Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
MiMedx Group Inc(MDXG)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MDXG
09/25/2026: MDXG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
MiMedx Group is a medical device company specializing in regenerative medicine, primarily known for its human placental tissue-based allografts used in wound care. The company has a notable portfolio backed by clinical research and is focused on driving growth through evidence-based sales in the surgical and wound care markets. While the business has established a solid market presence, investors should be aware of risks including intense competition from synthetic alternatives and potential shifts in healthcare reimbursement. Given its history of regulatory challenges, the stock is best suited for investors who can tolerate volatility and are monitoring the company’s ongoing success in clinical evidence generation and commercial execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company is in a growth phase but faces specific regulatory and competitive risks in the regenerative medicine space. |
| Momentum investor | Weak fit | Momentum is highly conditional on news flow and positive clinical or regulatory catalysts. |
| Value investor | Mixed fit | The valuation depends heavily on the company's ability to maintain high margins and defend its market share against newer technologies. |
| Dividend investor | Weak fit | The company does not pay a dividend as it is focused on growth and operational stability. |
| Low-risk investor | Weak fit | The stock carries inherent risks related to the medical device regulatory environment and historical volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on sector news and regulatory updates. |
| Valuation risk | Medium / high | Future performance expectations are priced into the stock, leaving little margin for error. |
| Competition risk (Regenerative medicine) | High | New synthetic products or improved rival allografts could erode market share. |
| Business quality | Medium | The business has improved, but still faces structural challenges related to its specific product focus. |
| Dividend income | Low / none | There is no current income component for shareholders. |
| Execution risk | Medium / high | Success relies on consistently executing sales strategies and maintaining compliance. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 13.52% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 687.35M USD | Price to earnings Ratio 117.75 | 1Y Target Price 7.4 |
Price to earnings Ratio 117.75 | 1Y Target Price 7.4 | ||
Volume (30-day avg) 1.1M shares | Beta 1.42 | 52 Weeks Range 3.03 - 7.97 | Updated Date 09/25/2026 |
52 Weeks Range 3.03 - 7.97 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.04 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Advanced Wound Care | EPIFIX and related placental tissue products sold to hospitals and wound care centers. | The company makes the majority of its money selling human tissue-based products that help chronic wounds heal. |
| Surgical Recovery | AMNIOFIX and other products used during surgical procedures to aid patient recovery. | This segment provides surgical doctors with specialized tools to assist in tissue repair after an operation. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 117.75 | Forward PE 19.53 | Enterprise Value 578.20M | Price to Sales(TTM) 1.94 |
Enterprise Value 578.20M | Price to Sales(TTM) 1.94 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA 28.33 | Shares Outstanding 145.93M | Shares Floating 114.77M |
Shares Outstanding 145.93M | Shares Floating 114.77M | ||
Percent Insiders 2.14 | Percent Institutions 77.68 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About MiMedx Group Inc
Exchange NASDAQ | Headquarters Marietta, GA, United States | ||
IPO Launch date 2007-08-22 | CEO & Director Mr. Joseph H. Capper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 808 | Website https://www.mimedx.com |
Full time employees 808 | Website https://www.mimedx.com | ||
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.